Miskin, Dhanashri P.
Herman, Susan T.
Ngo, Long H.
Koralnik, Igor J.
Funding for this research was provided by:
National Institutes of Health (R01 074409)
National Institutes of Health (R01 047029)
National Institutes of Health (R01 074995)
Article History
Received: 26 October 2015
Revised: 20 November 2015
Accepted: 8 December 2015
First Online: 16 December 2015
Compliance with ethical standards
:
: This study was supported by NIH grants R01NS 047029 and 074995.
: Dr. Miskin reports no disclosures or conflicts of interest. Dr. Herman is funded by NIH grants R01 047029 and 074409; received research grants from UCB Pharma, Sage Pharmaceuticals, Acorda Therapeutics, and the Epilepsy Therapy Development Project; received consulting fees from Eisai, Inc. and Biotie, Inc. Dr. Ngo is funded by NIH grant R01 047029. Dr. Koralnik is funded by NIH grants R01 047029 and 074995; has received a research grant from Biogen Idec and the National Multiple Sclerosis Society; served on scientific advisory boards for Hoffmann La Roche, GlaxoSmithKline, Merck Serono, and MedImmune; received consulting fees from Bristol Myers Squibb, Ono Pharmaceuticals, Merck Serono, Hoffmann La Roche, GlaxoSmithKline, Perseid Therapeutics, Vertex Pharmaceuticals, and Johnson & Johnson; is an Associate Editor for the <i>Annals of Neurology</i>; and receives royalties from <i>UpToDate</i> for topics on the management of HIV and CNS mass lesions and on PML.